Ny krystalform vi af agomelatin, fremgangsmåde til fremstilling deraf, og farmaceutiske sammensætninger, som indeholder den

A crystalline form VI of agomelatine having X-ray powder diffraction diagram and infra-red spectrum as given in the specification, is new. A crystalline form VI of agomelatine of formula (L1) having X-ray powder diffraction diagram and infra-red spectrum as given in the specification, is new. An ind...

Full description

Saved in:
Bibliographic Details
Main Authors Le Pape, Lionel, Lecouve, Jean-Pierre, Linol, Julie, Coquerel, Gérard
Format Patent
LanguageDanish
Published 23.01.2017
Subjects
ACYCLIC OR CARBOCYCLIC COMPOUNDS
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:A crystalline form VI of agomelatine having X-ray powder diffraction diagram and infra-red spectrum as given in the specification, is new. A crystalline form VI of agomelatine of formula (L1) having X-ray powder diffraction diagram and infra-red spectrum as given in the specification, is new. An independent claim is included for preparation of the crystalline form VI of agomelatine (L1). [Image] ACTIVITY : CNS-Gen.; Hypnotic; Tranquilizer; Antidepressant; Cardiovascular-Gen.; Immunomodulator; Muscular-Gen.; Neuroleptic; Anorectic; Analgesic; Anticonvulsant; Antidiabetic; Antimigraine; Cytostatic; Antiparkinsonian; Endocrine-Gen.; Nootropic. No biological data given. MECHANISM OF ACTION : Melatoninergic system receptor agonist; 5-Hydroxytryptamine 2c receptor antagonist. No biological data given.
Bibliography:Application Number: DK20080291042T